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Introduction 
Despite improved care, Streptococcus pneumoniae is still among the most common cause of 
bacterial meningitis (together with Neisseria meningitidis) in developed countries with almost a 
third of children left with life-long auditory and/or neurological sequelae and a case fatality rate 
around 10% (1, 2). An estimated 3 million new cases of pneumonia occur annually in Europe 
leading to around 31,000 deaths and although the exact burden of pneumococcal pneumonia is 
not known, it is assumed that S. pneumoniae is by far the leading bacterial pathogen causing 
pneumonia in industrialized countries (3). Among invasive pneumococcal diseases (IPD), 
bacteremia without a focus is undoubtedly the most common clinical presentation (4, 5). If 
untreated, it may evolve into focal invasive disease in 0-6% of children (6, 7). 
Based on capsule polysaccharide composition, S. pneumoniae is classified in 92 different 
serotypes forming 46 serogroups. In 2000 a conjugate vaccine has been licensed for use in 
children below 5 years of age in the USA. This first pneumococcal conjugate vaccine (PCV) 
contained capsular polysaccharide antigens of seven serotypes (4, 6B, 9V, 14, 18C, 19F and 
23F), each of them conjugated to a modified Diphteria toxin carrier protein. Very soon after the 
heptavalent conjugate vaccine (PCV7) was introduced a dramatic impact was seen on IPD in the 
USA (8). The 7 vaccine serotypes have been virtually eradicated from carriage in vaccinated 
children (9) and as a consequence transmission of these serotypes to unvaccinated population has 
been reduced with a subsequent reduction of disease due to these serotypes (10). In Europe, 
PCV7 was licensed in 2001. However, in the majority of EU countries, PCV7 was not introduced 
into the universal vaccination schedule before 2006; vaccination policies in the period between 
PCV7 marketing and its universal use widely differed across countries. In December 2010, 16 
countries had introduced PCV7 into the universal schedule at national level (11). 
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As some clinically important serotypes were not covered by the PCV7, extended valence 
vaccines have been developed. In 2009, two new conjugate vaccines have been licensed in 
Europe and thereafter marketed in many countries. One is a 10-valent vaccine (PCV10) 
containing antigens from the same seven serotypes than PCV7 together with capsular 
polysaccharide antigens from serotypes 1, 5 and 7F. They are conjugated for 8 of them to a 
surface protein D from H. influenzae and for 2 of them to modified Diphteria toxin and Tetanus 
toxoid, respectively. The other one is a 13-valent (PCV13), which contains capsular 
polysaccharide antigens from serotypes 1, 3, 5, 6A, 7F, 19A, all conjugated to the modified 
Diphteria toxin 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&mid=).  
This review describes the factors that may have influenced PCV7 vaccine impact and IPD burden 
across different settings in Western European countries and discusses why in Europe, overall 
vaccine impact seems more limited than in the USA (12-16).  
Impact of PCV7 vaccine in Europe: Incidence before and after PCV7 implementation 
Table 1 compares the change in overall IPD incidence in children <2 years before and after PCV7 
use in 9 European countries (only studies providing national data are included). Incidence 
declined in every study, but the percent reduction varied widely across countries, related – but not 
solely - to the vaccine uptake. All 3 countries (France, England & Wales and Germany) that used 
PCV7 universally for at least two years, with a vaccine uptake ≥75%, showed a significant 
decline in incidence, ranging from 30% to 65%. Three countries showed a high and significant 
reduction (ranging 45-57%) after only a year of PCV7 universal use (Germany, Norway and 
Denmark). The reduction in EU countries was however systematically lower than in the US, 
where IPD incidence in children <2 years declined by 69% after only one year of PCV7 universal 
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use (8). Interestingly, most EU countries showed a high reduction in PCV7 serotype incidence, 
ranging 67-96% in children <2 years of age (12, 15, 17-19), similar to the 78% reduction in the 
US (8), suggesting a high PCV7 effectiveness on vaccine serotypes.  
Assessing IPD burden and vaccine impact 
A classical method for determining and monitoring the IPD burden is the epidemiological 
surveillance, involving collection of data on IPD cases and on pneumococcal isolates.  
Many factors may influence the estimated burden of pneumococcal invasive disease. Some of 
them may increase (hence overestimate) the measured disease incidence or decrease (hence 
underestimate) it. 
Population or pneumococcal factors affecting the real disease burden 
Firstly, major variations are observed between developing industrialized countries in terms of 
living conditions, crowding and hygiene, which clearly influence nasopharyngeal carriage of S. 
pneumoniae,, a prerequisite to infection (20, 21). Secondly population transmission of S. 
pneumoniae in European countries may vary according to intensity of social contacts, attendance 
to day-care, which starts as early as 2 months of age in some countries (22). Thirdly, some 
populations seem to have genetic predisposing factors (which have not been elucidated yet) to 
developing IPD, such as American Indians (rates 10 times higher than those of non-native 
American children) or Australian aborigenes (23, 24). However, these populations also live in 
lower socio-economic conditions and higher promiscuity. Moreover there are some known 
immune deficiencies, which predispose to IPD such as HIV/AIDS, sickle cell anemia, leukaemia, 
transplant patients and these populations may account for a substantial proportion of IPD cases. 
In an US study for example, half of the adults less than 65 years of age with IPD were suffering 
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from HIV/AIDS (25). Fourth, pneumococcal factors may also play an important role in IPD 
burden as serotypes and/or genotypes have differing propensity to cause invasive disease (26-28), 
or even death (29, 30). Moreover, some serotypes, like serotype 2, which was causing 12 to 27% 
of lobar pneumonia at the beginning of the 20th century in Europe has ‘disappeared’ (31), 
although it is still present in some countries like Bangladesh (32). Others serotypes have yet 
unexplained cyclical patterns like serotype 1 in Northern Europe (33) and some serotypes cause 
large population outbreaks (serotype 1 and 5) (34).  The distribution of pneumococcal serotypes 
prior to vaccine introduction also most likely influenced the dynamic of replacement colonization 
and disease caused by non-PCV7 types. Indeed, in the first 1-2 years after universal use, non 
vaccine types (NVT) incidence did not increase in the US where PCV7 types were responsible 
for 80-90% of IPD in children less than 5 years of age (35). By contrast, it rose by 43-140% in 
the <2 years in the Netherlands, France, Belgium and England &Wales (12, 17, 19, 36), where 
PCV7 coverage was 50-60% prior to PCV7 introduction (35).  
Fifth, interventions such as antibiotic or vaccine use may influence the burden of disease. 
Antibiotics will reduce nasopharyngeal carriage and transmission of susceptible S. pneumoniae, 
among which will be some clinically important serotypes (serotypes 1, 5, 7F). In contrast, 
antibiotics will select for antibiotic resistant clones, many of which are included in PCV7. 
However antibiotic resistant NVT clones have emerged, such as 19A in the USA and many 
European countries (16, 37, 38).   
Factors biasing burden estimates 
IPD case identification 
Blood sampling for culture vary among countries, regions and medical practices. Some countries 
such as the USA had recommendations of systematic blood culturing in every young child with 
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fever without a focus in both in- and outpatients settings (39). A few studies have demonstrated 
that the IPD incidence increased parallel to the number of blood culture samples in a population 
(40, 41). 
S. pneumoniae detection in the laboratory 
Optimal recovery of S. pneumoniae in the laboratory can be impaired at several steps in the 
process. First, previous antibiotic use before sample collection will affect the sensitivity of the 
diagnosis. In case of IPD, both CSF and blood will yield culture negative results rapidly after the 
beginning of treatment (42, 43). Second, the pre-analytical phase is essential: samples need to be 
collected, transported and handled appropriately, as S. pneumoniae will not survive over a few 
hours if not incubated on appropriate medium. In children, collecting the weight-appropriate 
amount of blood to maximize the detection of circulating bacteria and using the adequate culture 
bottle was only performed in 35% of the cases in a recent study. Most often, insufficient quantity 
of blood was used (44). Third identification of S. pneumoniae by the laboratory requires minimal 
infrastructures and training. Two classic phenotypic tests are used to identify S. pneumoniae, bile 
solubility and optochin susceptibility, both of which have been shown to occasionally fail to 
provide correct identifications (45).  
Alternative laboratory techniques for S. pneumoniae detection 
To overcome these hurdles in identifying the causative pathogen of invasive bacterial diseases in 
children, alternative techniques have been tested based on antigen or nucleic acid detection. In 
one pediatric study in the USA, soluble pneumococcal polysaccharide antigens were detected by 
use of a rapid immunochromatographic test on urine of almost 100% children with S. 
pneumoniae bacteraemia, 75% with lobar pneumonia, but also in 8% of afebrile children (46). In 
other studies the role of S. pneumoniae carriage in the nasopharynx was underlined as a cause of 
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false positive results, rendering the use for diagnosis of suspected pneumococcal infections in 
children limited (47, 48). However, antigen detection has been used on pleural fluid with 
promising results (49). 
Molecular methods may allow for rapid and enhanced detection of S. pneumoniae in blood or any 
sterile fluid especially in the cases of culture negativation by previous antibiotic use (50). PCR 
detection may be based on different target genes. Classically ply and lytA genes (2 virulence 
genes) have been used, but false positive results may be seen with S. oralis or S. 
pseudopneumoniae and in more recent studies, cpsA, a gene which belongs to the capsular locus 
has been added as a target (45, 50). However, PCR detection of S. pneumoniae DNA in blood 
may also lack specificity in young children who commonly carry S. pneumoniae in the 
nasopharynx, with 17% false positive in healthy children (33% in less than 2 year-old) in one 
study (51). In another study on children 3-36 months of age presenting at emergency room with 
fever without a focus, 206/459 (45%) children had a positive PCR with a negative culture, 
whereas only 16% had a false positive PCR in the control group (52). PCR detection is thus 
certainly relevant on CSF or pleural fluid, but interpretation of a blood positive result must be 
cautious and linked to clinical presentation. The most recent studies using real time PCR and 
quantification of bacterial load (50, 53), offer promises of future development of these diagnostic 
tools. Several studies have attempted to use serology for pneumonia diagnosis. Protective levels 
however vary from one serotype to another, are depending upon age and carriage acquisition and 
require comparison of antibody level in an early and a convalescent sample. Serological testing 
has been performed for epidemiological studies which usually demonstrate good sensitivity for 
bacteremic pneumonia diagnosis, but limited use in blood culture negative pneumococcal 
pneumonia, mainly due to the lack of a gold standard (54). 
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Comprehensiveness of surveillance system 
Although nearly all EU countries have a national IPD surveillance system and a national 
reference laboratory for S. pneumoniae (11), surveillance methods, case definitions and 
population under surveillance are very heterogeneous across countries. In the era of conjugate 
pneumococcal vaccines, most EU countries reinforced their IPD surveillance systems to inform 
decisions on vaccine policies (11). Reporting rates have thus increased in many countries after 
PCV7 use, not only due to surveillance enhancement, but also to increased awareness. However, 
many studies do not adjust incidence rates to the level of under-reporting, though the magnitude 
of incidence changes before and after PCV7 use is also influenced by whether data are adjusted 
for under-reporting. For instance, in Belgium, incidence reduction in the <2 years was estimated 
at 23% without any adjustment, at 37% when incidence are adjusted for under-reporting (19); in 
Germany, incidence reduction was 45% and 56% respectively with and without adjustment for 
under-reporting (14). Moreover, EU national surveillance systems mostly report hospitalised 
cases, as blood cultures are generally limited to inpatient. Historically, the focus of surveillance 
in Europe has been meningitis (thus the most severe cases). Although nearly all EU countries 
started to report other invasive diseases after PCV7 introduction, most European countries still 
report a higher proportion of meningitis compared to US surveillance studies: the proportion of 
IPD cases in children <2 years that were meningitis (defined as S. pneumoniae isolation from 
CSF) in the pre-PCV7 period was 50%, 27%, 24% and 15% in Italy (55), France (13), Denmark 
(56), and Belgium (16) respectively, compared to 5% in the US ABC sentinel surveillance (57). 
As EU countries cover more severe IPD cases compared to the US, comparison of 
epidemiological changes across these two areas is difficult to interpret. 
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Conclusions 
PCV7 has had a significant impact on IPD in Europe, but the observed reduction in the incidence 
was overall lower than in the USA. A first contributing factor is the lower proportion of PCV7 
serotypes causing IPD prior to vaccine introduction in the EU compared to the US, with a higher 
rise of NVT. However, other factors are related to methods of estimating the vaccine impact: all 
EU surveillance systems include more severe cases and most have improved the reporting of IPD 
cases post-vaccine introduction, thus underestimating vaccine impact when the analysis does not 
adjust for changes in reporting. Impact studies that compare incidence before and after PCV7 
introduction are thus difficult to interpret and compare. It is of utmost importance that vaccine 
impact studies are designed controlling for the many biases and analyzed carefully. Progresses 
have been made to harmonize and improve IPD surveillance in European countries. Nevertheless, 
there is still a need to harmonize data analysis among countries and stay aware of the limitations 
of such studies and cautious in interpreting their results. There is also a need for high quality 
effectiveness studies to evaluate the extended valency PCV vaccines that have been recently 
introduced. 
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Table 1 Reported incidences of IPD in children < 2 years in European countries before and 
after PCV7 introduction 
Country Pre PCV7 IPD 
Incidence/10
5
 
Year PCV7 
marketed 
Year PCV7 
universal 
PCV7 
uptake
2
 
Post PCV7 IPD 
incidence/10
5
 
% reduction in 
incidence 
(significance) 
Belgium
1
 (19) 129.7  
(2002-03)  
2004 2007 79% 
(2008) 
82.4 
(2008) 
37 (SS) 
France (13) 30  
(2001-2002) 
2001 2006 44% 
(2006) 
24  
(2006) 
21 (SS) 
France (17) 32.7  
(1998-02) 
2001 2006 85% 
(2008) 
22.1  
(2007-08) 
33 (SS) 
Netherlands  (12) 34.5  
(2004-06) 
2001 2006 94% 
(2008) 
22.5 
(2006-09) 
35 (SS) 
England & Wales
1
 
(36) 
54.2 
(adjusted) 
2002 2006 85-92% 
(2009) 
23.6  
(2009-10, adjusted) 
56 (SS) 
Norway (18) 67.7  
(2004-05) 
2001 2006 80% 
(2006) 
32.6  
(2007) 
52 (SS) 
Ireland (58) 40.0  
(2008) 
2002 2008 88% 
(2010)
3
 
26.3  
(2009) 
37 (NA) 
Switzerland (59) 29.6 
(2001-05) 
2001 2005** 
 
50%* 
(2009)  
14.5  
(2009) 
51 (NA) 
Denmark (15) 54.8  
(2000-07) 
2001 2007 69% 
(2007) 
23.8  
(2008) 
57 (SS) 
Germany
1
 (14) 20.0  
(1997-03) 
2001 2006 80% 
(2007) 
11.0  
(2007-08) 
45 (SS) 
Germany (60) 20.0 
 (1997-2003) 
2001 2006 80% 
(2007) 
14.1 
(2008-09) 
30 (NA) 
1: incidence has been adjusted for the under-coverage and under-reporting of the surveillance system 
2: for full schedule (2+1 or 3+1) 
3: for 2 doses only as vaccine was introduced at the end of the study year (Sept 2008) 
* for 2 doses 
** free of charge in 2006 
SS: statistically significant 
NA: non available 
 
Opmerking [IL1]: Where is 1 
